G Bradley Cole Sells 10,000 Shares of EXACT Sciences Co. (NASDAQ:EXAS) Stock

Share on StockTwits

EXACT Sciences Co. (NASDAQ:EXAS) insider G Bradley Cole sold 10,000 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $90.30, for a total transaction of $903,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

G Bradley Cole also recently made the following trade(s):

  • On Thursday, November 21st, G Bradley Cole sold 28,016 shares of EXACT Sciences stock. The stock was sold at an average price of $80.38, for a total transaction of $2,251,926.08.

Shares of NASDAQ EXAS opened at $88.06 on Friday. EXACT Sciences Co. has a fifty-two week low of $75.35 and a fifty-two week high of $123.99. The company has a 50 day simple moving average of $91.82 and a two-hundred day simple moving average of $100.81. The company has a market capitalization of $11.66 billion, a price-to-earnings ratio of -51.50 and a beta of 1.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.75.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, October 29th. The medical research company reported ($0.31) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.10. EXACT Sciences had a negative net margin of 29.83% and a negative return on equity of 29.06%. The business had revenue of $218.81 million during the quarter, compared to the consensus estimate of $216.14 million. During the same quarter last year, the firm earned ($0.37) earnings per share. The business’s revenue for the quarter was up 85.0% on a year-over-year basis. On average, analysts forecast that EXACT Sciences Co. will post -1.62 earnings per share for the current fiscal year.

Several analysts have commented on the stock. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $109.00 price objective for the company in a report on Thursday, October 17th. Oppenheimer initiated coverage on shares of EXACT Sciences in a report on Thursday, September 26th. They issued an “outperform” rating and a $130.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of EXACT Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $110.00 target price for the company. BTIG Research initiated coverage on shares of EXACT Sciences in a research note on Friday, January 10th. They set a “buy” rating and a $127.00 target price for the company. Finally, Dougherty & Co initiated coverage on shares of EXACT Sciences in a research note on Friday, December 13th. They set a “buy” rating and a $120.00 target price for the company. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. EXACT Sciences currently has an average rating of “Buy” and a consensus price target of $122.06.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC increased its position in shares of EXACT Sciences by 129.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 497 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 280 shares in the last quarter. United Services Automobile Association bought a new stake in shares of EXACT Sciences during the fourth quarter valued at approximately $3,027,000. Patten & Patten Inc. TN increased its position in shares of EXACT Sciences by 24.4% during the fourth quarter. Patten & Patten Inc. TN now owns 19,062 shares of the medical research company’s stock valued at $1,763,000 after acquiring an additional 3,737 shares in the last quarter. DNB Asset Management AS increased its position in shares of EXACT Sciences by 22.6% during the fourth quarter. DNB Asset Management AS now owns 16,433 shares of the medical research company’s stock valued at $1,520,000 after acquiring an additional 3,025 shares in the last quarter. Finally, Polianta Ltd bought a new stake in shares of EXACT Sciences during the fourth quarter valued at approximately $1,183,000. 86.59% of the stock is owned by institutional investors.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: Liquidity

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Fiera Capital Corp Invests $1.09 Million in Pinterest
Fiera Capital Corp Invests $1.09 Million in Pinterest
Fiera Capital Corp Sells 468,443 Shares of iShares MSCI Saudi Arabia Capped ETF
Fiera Capital Corp Sells 468,443 Shares of iShares MSCI Saudi Arabia Capped ETF
Yamana Gold Inc.  Senior Officer Richard Campbell Sells 13,050 Shares
Yamana Gold Inc. Senior Officer Richard Campbell Sells 13,050 Shares
Fiera Capital Corp Reduces Holdings in Activision Blizzard, Inc.
Fiera Capital Corp Reduces Holdings in Activision Blizzard, Inc.
Fiera Capital Corp Sells 7,525 Shares of Lincoln Electric Holdings, Inc.
Fiera Capital Corp Sells 7,525 Shares of Lincoln Electric Holdings, Inc.
Vanguard S&P Small-Cap 600 ETF  Stock Holdings Lowered by Fiera Capital Corp
Vanguard S&P Small-Cap 600 ETF Stock Holdings Lowered by Fiera Capital Corp


© 2006-2020 Ticker Report